Join
Live feed
·
PRReleasevia Quantisnow
Recursion Pharmaceuticals Inc. logo

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

ByQuantisnow·Wall Street's wire, on your screen.
RXRX· Recursion Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RXRX (Recursion Pharmaceuticals Inc.) and more on Quantisnow.